We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Corvus Pharmaceuticals Inc (CRVS) USD0.0001

Sell:$1.73 Buy:$2.11 Change: $0.03 (1.57%)
Market closed |  Prices as at close on 21 June 2024 | Switch to live prices |
Change: $0.03 (1.57%)
Market closed |  Prices as at close on 21 June 2024 | Switch to live prices |
Change: $0.03 (1.57%)
Market closed |  Prices as at close on 21 June 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

Contact details

863 Mitten Rd Ste 102
United States
+1 (650) 9004520

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$116.97 million
Shares in issue:
62.55 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Richard Miller
    Chairman of the Board, President, Chief Executive Officer
  • Leiv Lea
    Chief Financial Officer
  • Jeffrey Arcara
    Senior Vice President, Chief Business Officer
  • William Jones
    Senior Vice President - Pharmaceutical Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.